GILEAD SCIENCES, INC. : Gilead Announces Interim Phase 2 Data for Idelalisib ... 4-traders (press release) ... idelalisib (formerly GS-1101), an investigational, targeted, oral inhibitor of PI3K delta, for the treatment of patients with indolent non-Hodgkin's lymphoma (iNHL) that is refractory (non-responsive) to rituximab and to alkylating-agent-containing ... Gilead Presents Idelalisib Data |
